While intracytoplasmic sperm injection (ICSI) has revolutionized the treatment of male factor infertility, a significant controversy still remains regarding its ubiquitous use in all IVF cycles. For patients without male factor infertility, does the addition of ICSI for fertilization offer a significant reproductive benefit? What are the risks and cost associated with such an approach?
Join our panel of REI fellow experts live from the PCRS 2022 Annual Meeting as they debate the role of ICSI in non-male factor infertility.
Questions to be addressed include:
- What are ICSI utilization rates and do they vary around the world?
- What non-male factor patients might benefit from ICSI?
- What are the potential short- and long-term risks of ubiquitous ICSI utilization?
- Is ICSI exploited as an "add-on" in ART?
Sarah Gavrizi, MD
Eduardo Hariton, MD, MBA
Ijeoma Iko, MD
Jerrine Morris, MD, MPH
Phillip Romanski, MD
Lauren Verrilli, MD
Alexander Quaas, MD, PhD